Biotech Values

[bladerunner1717]

Oldberkeley,

That's exactly the reason I questioned MNTA's tactics here in using the legal gambit--that I think doesn't have a prayer of succeeding--to get TEVA to shut up about the "imminent approval of generic Lovenox." The loss of the lawsuit may prove to be a bit troublesome. But maybe not too much. And as I mentioned, the absent spectator to this whole affair is the TEVA shareholder. When TEVA's generic doesn't get approved and the stock continues to tank, TEVA shareholder lawyers might want to take more than a cursory look backwards at MNTA's complaint.


I expect to hear less and less about TEVA's "imminent approval of generic Lovenox" from Bill and Shlomo.


Bladerunner